HilleVax (HLVX) Competitors

Eton Pharmaceuticals (NASDAQ:ETON) and HilleVax (NASDAQ:HLVX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking, media sentiment and dividends.

Is ETON or HLVX more profitable?

HilleVax has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -15.81%. Eton Pharmaceuticals' return on equity of -36.29% beat HilleVax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-15.81%	-36.29%	-16.84%
HilleVax	N/A	-67.27%	-51.99%

Does the MarketBeat Community prefer ETON or HLVX?

Eton Pharmaceuticals received 88 more outperform votes than HilleVax when rated by MarketBeat users. Likewise, 65.77% of users gave Eton Pharmaceuticals an outperform vote while only 58.82% of users gave HilleVax an outperform vote.

Company	Underperform	Outperform
Eton Pharmaceuticals	Outperform Votes 98 65.77%	Underperform Votes 51 34.23%
HilleVax	Outperform Votes 10 58.82%	Underperform Votes 7 41.18%

Which has more volatility and risk, ETON or HLVX?

Eton Pharmaceuticals has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500. Comparatively, HilleVax has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Do insiders and institutionals hold more shares of ETON or HLVX?

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 86.4% of HilleVax shares are held by institutional investors. 14.9% of Eton Pharmaceuticals shares are held by insiders. Comparatively, 71.1% of HilleVax shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Do analysts recommend ETON or HLVX?

Eton Pharmaceuticals presently has a consensus target price of $27.67, indicating a potential upside of 87.95%. HilleVax has a consensus target price of $3.00, indicating a potential upside of 71.92%. Given Eton Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eton Pharmaceuticals is more favorable than HilleVax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
HilleVax	0 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has preferable earnings & valuation, ETON or HLVX?

Eton Pharmaceuticals has higher revenue and earnings than HilleVax. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$34.68M	11.06	-$940K	-$0.22	-66.91
HilleVax	N/A	N/A	-$123.57M	-$3.10	-0.56

Does the media refer more to ETON or HLVX?

In the previous week, Eton Pharmaceuticals had 21 more articles in the media than HilleVax. MarketBeat recorded 22 mentions for Eton Pharmaceuticals and 1 mentions for HilleVax. Eton Pharmaceuticals' average media sentiment score of 0.50 beat HilleVax's score of 0.00 indicating that Eton Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
HilleVax	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Eton Pharmaceuticals beats HilleVax on 13 of the 17 factors compared between the two stocks.